Home Cart Sign in  
Chemical Structure| 1228013-15-7 Chemical Structure| 1228013-15-7
Chemical Structure| 1228013-15-7

CC-115

CAS No.: 1228013-15-7

CC-115 is an inhibitor ofmTOR andDNA-PK with IC50 of 21 and 13 nM respectively.

4.5 *For Research Use Only !

Cat. No.: A642364 Purity: 98+%

Change View

Size Price

US Stock

Global Stock

In Stock
5mg ł§ó¶ÊÊ Inquiry Inquiry
10mg łÿò¶ÊÊ Inquiry Inquiry
25mg łîÿ¶ÊÊ Inquiry Inquiry
50mg łÇÿʶÊÊ Inquiry Inquiry
100mg łË§Ê¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 5mg

    ł§ó¶ÊÊ

  • 10mg

    łÿò¶ÊÊ

  • 25mg

    łîÿ¶ÊÊ

  • 50mg

    łÇÿʶÊÊ

  • 100mg

    łË§Ê¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of CC-115

CAS No. :1228013-15-7
Formula : C16H16N8O
M.W : 336.35
SMILES Code : O=C1CN=C2C(N1CC)=NC(C3=C(C)N=C(C4=NN=CN4)C=C3)=CN2
MDL No. :MFCD29036965
InChI Key :GMYLVKUGJMYTFB-UHFFFAOYSA-N
Pubchem ID :58298318

Safety of CC-115

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of CC-115

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • DNA-PK

    DNA-PK, IC50:0.013 μM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
Multiple myeloma cells 1.5 nM to 10 µM 72 h CC-115 showed dose-dependent growth inhibition in multiple myeloma cells, and its effect was superior to the specific TORK inhibitor CC-223. PMC9892823
HCT 116 cells 0.1 µM to 3.5 µM 4 h CC-115 induced a dose-dependent increase in NMD transcripts in HCT 116 cells, indicating inhibition of SMG1-mediated NMD. PMC9892823
CAL33 1 µM 24 h CC-115 + IR treatment led to an elevation in G2/M arrest, increased cell death, and a synergistic reduction in cell proliferation, though the effect was notably lower compared to the AZD7648 + IR- treated group. PMC10887161
UM-SCC-47 1 µM 24 h CC-115 + IR treatment led to an elevation in G2/M arrest, increased cell death, and a synergistic reduction in cell proliferation, though the effect was notably lower compared to the AZD7648 + IR- treated group. PMC10887161
LNCaP-AR 1 μM 24 h reduced invasion and migration of CRPC cells PMC6744969
C4-2B 1 μM 24 h reduced invasion and migration of CRPC cells PMC6744969
LNCaP-AR-enza-res 1 μM 24 h reduced invasion and migration of enzalutamide-resistant CRPC cells PMC6744969
C4-2 0–25 μM 6 days Assessment of CC-115 in hormone-sensitive and castration-resistant prostate cancer models showed that CC-115 reduced cell viability in a dose-dependent manner and induced apoptosis. PMC6744985
22Rv1 0–25 μM 6 days Assessment of CC-115 in hormone-sensitive and castration-resistant prostate cancer models showed that CC-115 reduced cell viability in a dose-dependent manner and induced apoptosis. PMC6744985
Healthy donor skin fibroblasts (SBLF7) 0.1–25 μM 48 h To study the effect of CC-115 on cell death, results showed that cell death increased linearly with increasing concentration of CC-115. PMC7730287
Melanoma cells (ARPA) 0.1–25 μM 48 h To study the effect of CC-115 on cell death, results showed that melanoma cells were more sensitive to CC-115, with cell death reaching saturation at higher concentrations. PMC7730287
Melanoma cells (HV18MK) 0.1–25 μM 48 h To study the effect of CC-115 on cell death, results showed that melanoma cells were more sensitive to CC-115, with cell death reaching saturation at higher concentrations. PMC7730287
LOU-NH91 25.10 μM 72 h Assessed the IC50 value of CC-115 on LOU-NH91 cells, showing synergistic effects with carboplatin PMC9452486
H596 0.68 μM 72 h Assessed the IC50 value of CC-115 on H596 cells, showing synergistic effects with carboplatin PMC9452486
H1975 0.31 μM 72 h Assessed the IC50 value of CC-115 on H1975 cells, showing synergistic effects with carboplatin PMC9452486
TM00244 0.43 μM 72 h Assessed the IC50 value of CC-115 on TM00244 cells, showing synergistic effects with carboplatin PMC9452486
H226 0.95 μM 72 h Assessed the IC50 value of CC-115 on H226 cells, showing synergistic effects with carboplatin PMC9452486
Calu-1 1.38 μM 72 h Assessed the IC50 value of CC-115 on Calu-1 cells, showing synergistic effects with carboplatin PMC9452486
Atmfl/fl; LSL-KrasG12D/+; Ptf1aCre/+ (AKC) cells 30 nM 6 h To evaluate the effect of CC-115 on DNA replication dynamics PMC7948173
ATM+/Δ MIA PaCa-2 cells 30 nM 48 h To evaluate the synergistic effect of CC-115 in combination with PARPi and ATRi PMC7948173
LOU-NH91 0.2 μM 72 h CC-115 in combination with carboplatin showed synergistic effects in LOU-NH91 cells, significantly inhibiting cell viability. PMC9452486
Calu-1 0.4 μM 72 h CC-115 in combination with carboplatin showed synergistic effects in Calu-1 cells, significantly inhibiting cell viability. PMC9452486
H226 0.4 μM 72 h CC-115 in combination with carboplatin showed synergistic effects in H226 cells, significantly inhibiting cell viability. PMC9452486

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Mice Multiple myeloma xenograft model Oral 5 mg/kg Once daily until day 36 CC-115 showed significant antitumor activity in the multiple myeloma xenograft model, with a significant reduction in tumor volume and good tolerability. PMC9892823
CB17-SCID mice LNCaP-AR xenograft model oral 2 mg/kg 5 times per week for 6 weeks significantly delayed tumor growth PMC6744969
CB17 SCID mice Castration-resistant prostate cancer model Oral 2 mg/kg Once daily for 39 days Evaluation of the tumor growth inhibitory effects of CC-115 in combination with Enzalutamide in castration-resistant prostate cancer models showed that the combination treatment significantly increased tumor doubling time and improved survival rates. PMC6744985
mice LUSC PDX models oral gavage and I.P. injection 1 mg/kg once weekly for four weeks Evaluated the antitumor effect of CC-115 in combination with carboplatin and paclitaxel on LUSC PDX models, showing significant tumor growth inhibition and prolonged survival PMC9452486
Mice Subcutaneous tumor model Intraperitoneal injection 2.5 mg/kg Once daily for 17 days To evaluate the inhibitory effect of CC-115 in combination with PARPi and ATRi on the growth of ATM-deficient PDAC tumors PMC7948173
Mice LUSC patient-derived xenograft models Oral gavage (CC-115), Intraperitoneal injection (carboplatin and paclitaxel) 1 mg/kg Once weekly (carboplatin and paclitaxel), daily (CC-115), for four weeks CC-115 in combination with carboplatin and paclitaxel significantly inhibited tumor growth and extended survival in mice. PMC9452486

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01353625 Glioblastoma Multiforme|Squamo... More >>us Cell Carcinoma of Head and Neck|Prostate Cancer|Ewing's Osteosarcoma|Chronic Lymphocytic Leukemia|Neoplasm Metastasis Less << PHASE1 COMPLETED 2021-03-12 Cedars-Sinai Medical Center, L... More >>os Angeles, California, 90048, United States|UCLA, Los Angeles, California, 90095, United States|University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute, San Francisco, California, 94115, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, 48202, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, 37203, United States|Mary Crowley Medical Research Center, Dallas, Texas, 75201, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77303, United States|Gustave Roussy, Villejuif Cedex, 94805, France|Uniklinik Koln, Koeln, 50937, Germany|Universitatsklinikum Wurzburg, Würzburg, 97070, Germany|Hospital Val d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, 28050, Spain|Hospital de Donosti, San Sebastián (Guipuzcoa), 20014, Spain|Hospital Virgen del Rocio, Sevilla, 41013, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.87mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

References

 

Historical Records

Categories